A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...